Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Curevac N.V.
(NQ:
CVAC
)
3.130
+0.360 (+13.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Curevac N.V.
< Previous
1
2
3
4
5
6
7
8
9
Next >
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
April 24, 2024
Via
ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
April 24, 2024
Via
ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
April 24, 2024
Via
ACCESSWIRE
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
April 18, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
November 14, 2023
Via
ACCESSWIRE
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
April 16, 2024
Via
ACCESSWIRE
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
April 12, 2024
Via
Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
April 04, 2024
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A...
Via
Benzinga
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
April 04, 2024
Via
ACCESSWIRE
Why Biopharmaceutical Player CureVac Shares Are Rising Today
January 05, 2024
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.
Via
Benzinga
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
January 05, 2024
Via
ACCESSWIRE
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 19, 2023
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy...
Via
Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
December 19, 2023
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
December 19, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
December 19, 2023
Via
ACCESSWIRE
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
November 15, 2023
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Earnings Scheduled For November 14, 2023
November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
Via
Benzinga
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
November 01, 2023
Via
ACCESSWIRE
Why CureVac Stock Plunged Today
September 29, 2023
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 28, 2023
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant...
Via
Benzinga
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
August 17, 2023
Via
ACCESSWIRE
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
August 01, 2023
Via
ACCESSWIRE
CureVac Announces Update to the Management Team
July 14, 2023
Via
ACCESSWIRE
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
July 13, 2023
Via
ACCESSWIRE
Why Shares of CureVac Jumped This Week
June 23, 2023
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
Via
The Motley Fool
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 27, 2023
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Via
Benzinga
Why CureVac Stock Leaped 12% Higher Today
June 20, 2023
The war on cancer advances with the German company's latest clinical development.
Via
The Motley Fool
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
June 20, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.